Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739758) titled 'A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naive Extensive-stage Small Cell Lung Cancer' on July 28.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Condition:
SCLC, Extensive Stage
Intervention:
Drug: YL201
Drug: Serplulimab
Drug: Carboplatin
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: August 2026
Target Sample Size: 442
Countries of Recruitment:
China
To know more...